Inactive Instrument

China Biotech Services Holdings Limited Stock Hong Kong S.E.

Equities

8037

BMG7713H1575

Healthcare Facilities & Services

Sales 2022 1.85B 237M Sales 2023 212M 27.08M Capitalization 742M 94.75M
Net income 2022 258M 32.96M Net income 2023 -95M -12.14M EV / Sales 2022 0.59 x
Net cash position 2022 10.99M 1.4M Net Debt 2023 28.31M 3.62M EV / Sales 2023 3.63 x
P/E ratio 2022
4.29 x
P/E ratio 2023
-7.77 x
Employees -
Yield 2022
0.87%
Yield 2023
-
Free-Float 35%
More Fundamentals * Assessed data
Dynamic Chart
China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Biotech Services Holdings Limited announced that it expects to receive HKD 88 million in funding CI
China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023 CI
Pengbo Medical Technology Co., Ltd. Announces the Approval by the Hainan Provincial Medical Products Administration for the Import of Medical Devices CI
China Biotech Services Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
China Biotech Services Holdings Limited Provides Group Earnings Guidance for the Nine Months Ended September 30, 2023 CI
China Biotech Services Holdings Limited Announces Strategic Cooperation Framework Agreement with Astrazeneca Investment Co., Ltd CI
China Biotech Services Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
China Biotech Services Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023 CI
China Biotech Services Holdings Limited Announces Redesignation of Chui Hoi Yam from an Executive Director to Non-Executive Director CI
China Biotech Services Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
China Biotech Services Holdings Limited and The Chinese University of Hong Kong Enter into Memorandum of Understanding CI
China Biotech Services Holdings Limited Provides Group Earnings Guidance for the Three Months Ended 31 March 2023 CI
China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022 CI
China Biotech Services Holdings Limited announced that it has received HKD 77.8 million in funding from Guoyuan Securities Investment (Hong Kong) Limited CI
More news
China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.
More about the company